Skip to content

Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)

Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02602457
Enrollment
94
Registered
2015-11-11
Start date
2015-11-30
Completion date
2030-10-31
Last updated
2022-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation

Brief summary

Atrial fibrillation is the most common heart rhythm disorder. The management of atrial fibrillation is of great importance. Despite the presence of exercise intolerance, weight gain, and an associated decline in overall health and well-being in patients living with atrial fibrillation, recommended standard care does not currently include the prescription of exercise to address these significant health issues. Exercise training is a recognized form of treatment of persons with heart disease. An exercise program such as high-intensity interval training when compared to moderate-intensity continuous exercise training may provide a stronger training stimulus for exercise and clinical outcomes; may be more efficient and motivating; and, may help to improve adherence to exercise training in persistent or permanent atrial fibrillation patients. This has been shown in patients with coronary artery disease and heart failure. The primary objectives of this prospective study are to examine the impact of high-intensity interval training compared to moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.

Detailed description

Atrial fibrillation is the most common heart rhythm disorder. Significant disease and death rates are associated with atrial fibrillation because of stroke risk, the complications of medications, poor quality of life and reduced exercise tolerance. Many patients report they have a lower quality of life because of this condition, so finding new ways of helping patients manage and cope with this health problem may help a great number of people. The management of atrial fibrillation is of great importance. Despite the presence of exercise intolerance, weight gain, and an associated decline in overall health and well-being in patients living with atrial fibrillation, recommended standard care does not currently include the prescription of exercise to address these significant health issues. Exercise training is a recognized form of treatment of persons with heart disease. An exercise program such as high-intensity interval training when compared to moderate-intensity continuous exercise training may provide a stronger training stimulus for exercise and clinical outcomes; may be more efficient and motivating; and, may help to improve adherence to exercise training in persistent or permanent atrial fibrillation patients. This has been shown in patients with coronary artery disease and heart failure. The primary objectives of this prospective study are to examine the impact of high-intensity interval training compared to moderate-intensity continuous exercise training in adults with persistent or permanent atrial fibrillation on exercise capacity and quality of life.

Interventions

BEHAVIORALmoderate-intensity continuous exercise training

Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.

BEHAVIORALhigh-intensity interval training

Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.

Sponsors

Ottawa Heart Institute Research Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. persistent or permanent atrial fibrillation; 2. rate controlled with a resting ventricular rate of equal to or less than 110 bpm; 3. able to perform a symptom-limited exercise test; 4. at least 40 years of age; 5. patient agrees to sign informed consent.

Exclusion criteria

1. currently participating in routine exercise training (more than two times per week); 2. unstable angina; 3. uncontrolled diabetes mellitus; 4. diagnosed severe mitral or aortic stenosis; 5. diagnosed hypertrophic obstructive cardiomyopathy with significant obstruction; 6. unable to provide written, informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Change in quality of life as measured by the Short-Form 36 questionnairebaseline to 12 weeksChange in quality of life from baseline to 12 weeks as measured by the Short Form-36 questionnaire.
Change in exercise capacity as measured by six-minute walk test distancebaseline to 12 weeksChange in exercise capacity from baseline to 12 weeks as measured by six-minute walk test distance.

Secondary

MeasureTime frameDescription
Change in symptom burden measured by the Canadian Cardiovascular Society Severity of Atrial Fibrillation scalebaseline to 12 weeksChange in symptom burden from baseline to 12 weeks as measured by the Canadian Cardiovascular Society Severity of Atrial Fibrillation scale.
Change in symptom frequency and severity measured using the 7-day symptom diarybaseline to 12 weeksChange in symptom frequency and severity from baseline to 12 weeks as measured using the the 7-day symptom diary.
Change in disease specific quality of life will be measured using the University of Toronto Atrial Fibrillation Severity Scale (AFSS)baseline to 12 weeksChange in disease specific quality of life from baseline to 12 weeks will be measured using the University of Toronto Atrial Fibrillation Severity Scale (AFSS).
Change in anxiety and depressive symptoms will be measured using the Hospital Anxiety and Depression Scale (HADS)baseline to 12 weeksChange in anxiety and depressive symptoms from baseline to 12 weeks will be measured using the Hospital Anxiety and Depression Scale (HADS).
Change in sleep apnea risk will be measured by the STOP-BANG Sleep Apnea Questionnairebaseline to 12 weeksChange in risk of sleep apnea from baseline to 12 weeks will be measured by the STOP-BANG Sleep Apnea Questionnaire.
Change in exercise adherence measured by accelerometerbaseline to 12 weeksChange in exercise adherence from baseline to 12 weeks as measured by accelerometer.
Change in self reported sleep patterns will be measured using a 7-day sleep diarybaseline to 12 weeksChange in self reported sleep patterns from baseline to 12 weeks will be measured using a 7-day sleep diary.
Change in heart rate control will be measured using 24-hour Holter ECG recordings and ECG recordings at each cardiopulmonary exercise test (CPET)baseline to 12 weeksChange in heart rate control from baseline to 12 weeks will be measured using 24-hour Holter ECG recordings and ECG recordings at each cardiopulmonary exercise test (CPET)
Change in muscular fitness will be measured using standard load testsbaseline to 12 weeksChange in muscular fitness from baseline to 12 weeks will be measured using standard load tests.
Change in exercise capacity will be measured using a cardiopulmonary exercise test (CPET)baseline to 12 weeksChange in exercise capacity from baseline to 12 weeks will be measured using a cardiopulmonary exercise test (CPET)
Insomnia severity index will be measured using the Insomnia Severity Indexbaseline to 12 weeksInsomnia severity index at baseline and 12 weeks will be measured using the Insomnia Severity Index.
Change in activity status measured by the Duke Activity Status Indexbaseline to 12 weeksChange in activity status from baseline to 12 weeks as measured by the Duke Activity Status Index.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026